Thermo Fisher to acquire Qiagen for $11.5 billion

3 March 2020

Having failed in its attempt last year to take over the Dutch molecular diagnostics company last year, Thermo Fisher Scientific (NYSE: TMO) today announced that it has reached agreement to acquire Qiagen (NYSE: QGEN) for 39 euros per share in cash, a 23% premium to the closing price on Monday.

The transaction values Qiagen at around $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt. Qiagen’s shares were 16.14% higher at $41.95 in pre-market trading today.

"We are excited to bring together our complementary offerings to advance our customers' important work, from discovery to diagnostics," said Marc Casper, chairman, president and chief executive of Thermo Fisher Scientific. "This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies," he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK